BMY241206C64000
- 0.01
- -0.05-83.33%
Bristol-Myers Squibb Newsroom
Express News | CFRA has downgraded bristol-myers squibb's rating to hold, with a target price of 60 dollars.
PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
AI Proteins Announces Research Collaboration and Option Agreement With Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M
Bristol-Myers Squibb Company (BMY): Close to Becoming a Dividend Aristocrat
Ovarian Cancer Therapeutics Business Research Report 2024-2030, Profiles of 12 Players Including Amgen, AstraZeneca, and Bristol-Myers Squibb Company
Is Bristol-Myers Squibb Stock a Millionaire Maker?
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Express News | Bristol-Myers Squibb's three innovative drugs have been included in the 2024 National Medical Insurance Catalog.
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference
Bristol-Myers Squibb Hits 14-month High
Merck Phase 3 Study of Winrevair in PAH Meets Primary Endpoint
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating
Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Cobenfy Projections and Competitive Advantages
Pension Doubles Its Palantir Stake and Buys Up Intel and CVS. -- Barron's
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Replimune Climbs After Updates on Lead Drug
Optimism Over Global Healthcare Sector Rises: Jefferies
Investing in Bristol-Myers Squibb (NYSE:BMY) a Year Ago Would Have Delivered You a 24% Gain
BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD